QURE News and Press, uniQure N.V. From 05/02/22

LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, including one oral presentation, will be d...

uniQure press release (NASDAQ:QURE): Q1 GAAP EPS of -$1.00 misses by $0.20. Revenue of $1.79M (+297.8% Y/Y) misses by $0.67M. As of March 31, 2022, the Company had cash and cash equivalents of $524.9 million, which included the collection of $20 million of the $55 million in milestone payment...

~ Partner CSL Behring submitted Marketing Authorization Application (MAA) in Europe for etranacogene dezaparvovec in hemophilia B; MAA validated by the European Medicines Agency (EMA) and granted accelerated assessment ~ ~ Received $55 million in milestone payments ass...

Pharmaceuticals and biotechnology still are attractive regarding value and quality. Other subsectors are overvalued by 15% to 42% relative to 11-year averages. Fast facts on IBB. 10 healthcare stocks cheaper than their peers in April. For further details see: IBB: He...

The primary and secondary endpoints for HOPE-B were met when patients with Hemophilia B were treated with etranacogene dezaparvovec. Marketing applications for etranacogene dezaparvovec for the treatment of patients with Hemophilia B will be submitted in both the U.S. and EU in the 1s...

The European Medicines Agency accepted a marketing authorization application by CSL's (OTCPK:CSLLY) unit CSL Behring's for gene therapy etranacogene dezaparvovec (EtranaDez) to treat hemophilia B. Etranacogene dezaparvovec is administered as a one-time treatment for patients&#x...

European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B PR Newswire Marketing Authorization Application (MAA) for etranacogene dezaparvovec will be reviewed under accelerated assessment and has the...

uniQure (NASDAQ:QURE) completed patient enrollment in the first two cohorts of Phase I/II trial of its therapy, AMT-130, to treat early stage Huntington’s disease. The early-to-mid stage study includes two dose cohorts of 26 patients randomized to either treatment with the company...

LEXINGTON, Mass. and AMSTERDAM, March 21, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first two cohorts of its ...

uniQure (QURE +4.2%) is trading higher for the third straight session after UBS upgraded the shares of the Dutch biotech to Buy from Neutral, citing an attractive long-term risk-reward profile ahead of key milestones expected in the next 1 – 2 years. The analysts led by Eliana Merle po...